The PROSPER and SPARTAN studies are impacting standard of care
Tomasz M. Beer, MD, talks about how the the PROSPER (enzalutamide) and SPARTAN (apalutamide) studies in non-metastatic castrate-resistant prostate cancer are impacting standard of care at ASCO 2018.
Author: obr
Added: 07/18/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts